NUMINUS WELLNESS INC. (TSX-V:NUMI)
Numinus Wellness Inc. (TSX-V:NUMI) is positioned to become a market leader in psychedelic medical treatments. The company is at the forefront of this exciting, emergent industry.
Following 50 years shut out in the regulatory wilderness, psychedelic-assisted psychotherapies are now attracting international research interest like never before.
Leading government healthcare bodies and pharmaceutical companies have woken up to the immense potential in naturally-derived psilocybin as a solution to treatment-resistant depression.
Importantly, Health Canada, the U.S. Federal Drug Administration, and the United States Department for Health and Human Services are leading the charge.
In 2019, the FDA twice designated psilocybin as a “breakthrough therapy”, which could ultimately help treat the 17 million Americans with major depressive disorders.
Breakthrough status is only granted when evidence suggests a treatment may be an enormous improvement over already-available therapies.
In Canada, Numinus’s home country, Health Canada just weeks ago granted an exemption to four cancer patients facing end-of-life anxiety making them the first known patients to legally use psilocybin since the compound became illegal in Canada in 1974.
Landmark regulatory moves such as these will accelerate the normally torpid process to research and approve new medicines.
Riding the crest of this new wave is Numinus, which is developing psilocybin-based psychotherapy protocols backed by strict standardization rules and scientific rigour.
It broke new ground earlier this year when it became the first publicly listed company to be awarded a coveted license from Health Canada to produce and extract psilocybin from mushrooms.
BREAKING NEWS: Numinus announces closing of oversubscribed $4.6 Million offering.
NUMINUS WELLNESS INC. (TSX-V:NUMI)
In this exclusive webinar, ValueTheMarkets editor Ben Turney talks to Numinus CEO Payton Nyquvest about:
- Why the recent consolidation in the psychedelic-assisted psychotherapy market presents such an attractive buying opportunity
- How quickly the Numinus clinical and R&D model will produce material results
- How upcoming regulatory shifts will set the stage for a transformation in this market
- Why a little-known Section 56 exemption for cancer patients is so important and what it signals about the increasing pace of official acceptance of psychedelic therapies
- How fast health controllers are switching from an apprehensive to supportive stance
- Why a paid-for, revenue-ready 7,000sq ft lab facility is central to Numinus’ plans
- How the company plans to deploy the funds it is currently raising and the major milestones it aims to achieve over the next year
- Other potential major catalysts in the market and within Numinus that could trigger a fundamental rerate in the company’s stock price
“We see this as a very, very exciting opportunity as you’re going to see regulation change imminently.”Payton Nyquvest, Founder and CEO, Numinus
Watch the webinar NOW to find out how you can profit on where Numinus goes next.
READ OUR SPECIAL REPORT – TO DISCOVER HOW NUMINUS’ (TSX-V:NUMI) EXPERT TEAM IS AT THE FOREFRONT OF DEVELOPING HEALING TREATMENTS FOR THE MIND
IMPORTANT NOTICE AND DISCLAIMER
This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Numinus Wellness Inc. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred and thirty six thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.
CHANGES IN SHARE TRADING AND PRICE
Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.
NO OFFER TO SELL OR BUY SECURITIES
This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.
Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.
This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.
NO FINANCIAL ADVICE
The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.
FORWARD LOOKING STATEMENTS
This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.
All trademarks used in this communication are the property of their respective trademark holders. Other than valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than valuethemarkets.com.
valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.
ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of valuethemarkets.com, has been paid for the production of this piece by the company or companies mentioned above.